Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)
Study Details
Study Description
Brief Summary
The purpose of this study is to initially access the safety and effectivity of RC18 combined with standard treatment and Placebo combined with standard therapy in subjects with Moderate to severe SLE.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: RC18 160mg Patients received the test group RC18 160mg weekly administered subcutaneously for 52 times. |
Biological: RC18 160 mg plus standard therapy
Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,Tacrolimus ,ciclosporin )
Other Names:
|
| Placebo Comparator: Placebo Patients received the test group Placebo weekly administered subcutaneously for 52 times. |
Biological: Placebo plus standard therapy
Standard therapy comprises any of the following (alone or in combination):
corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,Tacrolimus ,ciclosporin )
Other Names:
|
Outcome Measures
Primary Outcome Measures
- SLE Responder Index (SRI) Response Rate [Week 52]
At Week 52 the percent of subjects with ≥ 4 point reduction from baseline in SELENA-SLEDAI score and increasing no more than 0.3 points in PGA and no new BILAG A organ domain score or 1 new BILAG B organ domain scores compared with baseline at the time of assessment
Secondary Outcome Measures
- Percent of subjects with ≥ 4 point reduction from baseline in SELENA-SLEDAI score [Week 52]
- Mean Change From Baseline in Physician's global assessment(PGA) [Week 52]
Physician's global assessment, PGA.The measurement tool is Visual Analogue Scale/Score（VAS）.The doctor assesses participant's disease activity on a VAS of 0-100 mm on the questionnaire form.The higher values represent a worse outcome.There are not combined subscales.
- Percent of Subjects Whose Average Prednisone Dose Has Been Reduced by ≥ 25% From Baseline or ≤ 7.5 mg/Day，During Weeks 44 Through 52. [Week 44 through 52]
- Mean Change From Baseline in Serological Examination Index [week 52]
- The flare time after randomization [52 weeks]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Active SLE disease#and at least according with 4 of the 11 items of the American College of Rheumatology (ACR) criteria 1997.
-
Age & Gender: Male or female between 18 and 65 years of age inclusive#and the sex ratio is not limited
-
Signed informed consent form#willing or able to participate in all required study evaluations and procedures.
-
SELENA-SLEDAI(Safety of Estrogens in Lupus Erythematosus National Assessment SLE Disease Activity Index) score ≥ 8 during the screening period.and if there is Hypo-complement or the Anti-dsDNA score, SELENA-SLEDAI disease activity score should be at least 6 at screening .
-
Autoantibody-positive
-
on a stable SLE treatment regimen for at least 30 days prior to Day 1, which consisted of any of the following (alone or in combination): cortical hormone,anti-malarials,non-steroidal anti inflammatory drugs (NSAIDs),or any immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate
Exclusion Criteria:
-
kidney disease ：Severe lupus nephritis 8 weeks prior to randomization (designed as:Urine protein>6g/24h or serum creatinine ( SCr>2.5mg/dL or 221umol/L ) or needing for hemodialysis or receipting high dose cortical hormone ≥14 days( metacortandracin>100mg/d or equivalent)
-
Central nervous system disease caused by SLE or non SLE 8 weeks prior to randomization (including epilepsy、 mental disease、organic encephalopathy syndrome、cerebrovascular accident, encephalitis, central nervous system vasculitis;
-
there are serious heart, liver, kidney and other important organs and blood, endocrine system diseases and medical history;
Evaluation criteria for severity :
-
Alanine aminotransferase#ALT#or aspartate aminotransferase (AST) ≥2 upper limit of normal (ULN);
-
Creatinine Clearance (Ccr)<30ml/min;
-
White Blood Cell Count(WBCs)<2.5x 10(9)/L;
-
hemoglobin<85g/L;
-
Platelets<50x 10(9)/L.
-
Have a historically active hepatitis or active hepatitis or medical history,hepatitis B :Patients with positive HBsAg are excluded.;Hepatitis C: Patients with hepatitis C antibody positive are excluded;
-
Immune deficiency, uncontrolled severe infection and patients with active or recurrent peptic ulcer;
-
Pregnant , lactating women and men or women who have birth plans in the past 12 months ;
-
Have a history of allergic reaction to human biological medicines.
-
Receipt of live vaccine within 1 month;
-
Have participated in any clinical trial in the first 28 days of the initial screening or 5 times half-life period of the study compound (taking the time for the elderly).
-
Have received treatment with B cell targeted therapy such as Rituximab or Epratuzumab etc.
-
Receipt of anti-tumor necrosis factor#interleukin receptor antagonist#
-
Receipt of IV immunoglobulin(IVIG),prednisone>100mg/d more than 14 days or plasma exchange;
-
There are active infections (such as herpes zoster, human immunodeficiency virus (HIV) virus infection, active tuberculosis, etc.) during the screening period;
-
Patients have depression or the significant suicide ideation;
-
Interleukin(IL)-2, thalidomide, Tripterygium wilfordii and traditional Chinese medicine preparation containing Tripterygium Wilfordii were used within 28 days before randomization
-
Investigator considers candidates not appropriating for the study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Remegen，ltd. | Yantai | Shandong | China |
Sponsors and Collaborators
- RemeGen Co., Ltd.
Investigators
- Principal Investigator: Fengchun Zhang, M.D., Peking Union Medical College Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 18C010